Tamoxifen

Basic Information

CAS ID: 10540-29-1
Molecular Formula: C26H29NO
Molecular Weight: 371.5 g/mol
Monoisotopic Mass: 371.2249 g/mol
Class: Small Molecule
Natural Product: No
Other Names: Nolvadex | SOLTAMOX | TAMOXIFEN CITRATE | Soltamox | NOLVADEX D | ICI 46,474 | KESSAR 10 | KENTADEX | NOLVADEX | KESSAR 20 | FENTAMOX 10 | Kessar | Tamoxifen | OESTRIFEN-40 | OESTRIFEN-10 | ICI-46474 | FENTAMOX 20 | NOLVADEX FTE | TAMOFEN | Zynoplex | EMBLON | NOLTAM | OESTRIFEN-20
Analysis: Drug repositioning mechanism analysis

O N

Compound Structure and Identifier

InChI: InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- See All
InChI Key: NKANXQFJJICGDU-QPLCGJKRSA-N
Smiles: CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3 See All
Molfile: Download

Related Target

Related Fibrosis Property

Reference Record 1

PubMed ID 21242678 Target ID
Uniprot ID Name
Model vitro,rat Fibrosis Disease Peritoneal fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism Targeting CTGF

Reference Record 2

PubMed ID 22298115 Target ID
Uniprot ID Name
Model vitro,human Fibrosis Disease Keloid
Process I
Process II cells apoptosis
Process III
Mechanism

Trial Record 1

ClinicalTrial ID NCT00440349 Disease Retroperitoneal fibrosis
Phase Phase 2 Status Unknown
First Received February 27, 2007 Last Verified February 27, 2007
Sponsor University of Parma

Trial Record 2

ClinicalTrial ID NCT00896155 Disease Pulmonary fibrosis,
Phase Phase 3 Status Unknown
First Received May 11, 2009 Last Verified August 30, 2011
Sponsor Tata Memorial Hospital

Trial Record 3

ClinicalTrial ID NCT00999921 Disease Breast fibrosis
Phase Phase 4 Status Completed
First Received October 22, 2009 Last Verified May 18, 2015
Sponsor Medical College and Hospital Kolkata

Related Link

PubChem: 2733526
ChEMBL: CHEMBL83